Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and membranous glomerulonephritis (MGN) are both autoimmune disorders that are rarely observed concurrently. We describe a patient who developed MGN nearly 20 years after the onset of CIDP, resulting in a secondary progression of his neuropathy. He responded dramatically to a novel regimen of plasma exchange and methotrexate. We propose a mechanism other than autoimmunity for the coincidence of these disorders and discuss the theoretical superiority of the treatment regimen that he received.
MeSH terms
-
Adult
-
Age of Onset
-
Autoimmune Diseases / immunology*
-
Autoimmune Diseases / physiopathology
-
Disease Progression
-
Glomerulonephritis, Membranous / complications*
-
Glomerulonephritis, Membranous / immunology*
-
Glomerulonephritis, Membranous / physiopathology
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Kidney / immunology
-
Kidney / physiopathology
-
Male
-
Methotrexate / therapeutic use
-
Peripheral Nerves / immunology
-
Peripheral Nerves / physiopathology
-
Plasmapheresis
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / complications*
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / immunology*
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / physiopathology
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Methotrexate